GSK, Vir Biotech expanding cooperation - Breaking The News

GSK, Vir Biotech expanding cooperation

17 February

1 min read

EPA-EFE/OLIVIER HOSLET

GlaxoSmithKline plc and Vir Biotechnology Inc. have agreed to expand their joint research and development program to include new treatments for respiratory viruses.

Under the terms of the new deal, GSK will increase its equity investment in the California-based biotech firm by $120 million and make an upfront payment of $225 million. Additionally, Vir could receive up to $200 million based on the successful delivery of pre-defined milestones.

The two companies initially started working together on COVID-19 therapies in April 2020.

gsk vir biotechnology coronavirus

Related Stocks

Vir Biotechnology

GlaxoSmithKline

GSK's 2024 sales rise by 7% to £31.4 billion

5 February

GSK PLC announced on Wednesday that its sales in the fiscal year 2024 saw a yearly growth of 7% at the Constant Exchange Rate to reach £31.4 billion. On the other hand, its operating profit decreased by 33% compared to the previous year to land at £4 billion. The earnings per share (EPS) declined by 40% year-on-year to 63.2 pence."Our outperformance and stronger balance sheet support these investments [in Respiratory, Immunology & Inflammation,...

GSK to acquire IDRx for up to $1.15 billion

13 January

GSK plc announced on Monday that it agreed to acquire the United States biopharmaceutical company IDRx, Inc. for an upfront payment of $1 billion, with a possibility of an additional success-based payment of $150 based on regulatory approval.The acquisition includes a highly selective KIT tyrosine kinase inhibitor (TKI), IDRX-42, which is being developed as a treatment for gastrointestinal stromal tumors (GIST). According to GSK, IDRX-42 demonstrated...

GSK's Q3 sales up by 2% to £8 billion

30 October

GSK PLC announced on Wednesday that its revenue in the third quarter of the fiscal year 2024 observed an annual increase of 2% to reach £8 billion, missing market's expectations.On the other hand, the pharmaceutical company's operating profit plunged by 86% compared to the same period the year before to land at £186 million. Meanwhile, loss per share landed at 1.4 pence. For the 2024 outlook, GSK expects turnover growth of 7% to 9% and core...

Harris slams Trump for 'admiring dictators'

22 October

United States Vice President Kamala Harris, the Democratic presidential nominee, spoke in a recent NBC News interview about the choice Americans face in the upcoming election. She contrasted herself with former President Donald Trump, saying that voters must decide whether they want a leader who she claims openly admires authoritarian figures or not. "The American people are being presented with a choice here about whether we want a president who...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.